Vivani Medical Signs Agreement with Novo Nordisk to Evaluate NPM-139
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Vivani Medical (VANI) announced the signing of a new agreement with Novo Nordisk (NVO) to enable Novo Nordisk to evaluate NPM-139, the company's semaglutide drug implant. NPM-139, which utilizes Vivani's NanoPortal platform technology, is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani's proprietary NanoPortal technology associated with this agreement. Separately, Vivani expects to initiate a Phase 1, randomized, first-in-human study evaluating the NPM-139 semaglutide implant, with Wegovy injections as an active comparator, in mid-2026. The study's objectives are to characterize the safety, pharmacokinetics, and tolerability of NPM-139 to support the initiation of a Phase 2 dose-ranging study pending successful results of the Phase 1 study.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VANI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VANI
Wall Street analysts forecast VANI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.300
Low
4.00
Averages
4.00
High
4.00
Current: 1.300
Low
4.00
Averages
4.00
High
4.00
About VANI
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vivani Medical Partners with Novo Nordisk for Semaglutide Implant Evaluation
- New Agreement: Vivani Medical has entered into a partnership with Novo Nordisk to evaluate its NPM-139 semaglutide implant for chronic weight management, marking a significant collaboration in the biopharmaceutical sector.
- Clinical Trial Plans: Vivani expects to initiate a Phase 1 randomized clinical trial for NPM-139 in mid-2026, comparing its safety and tolerability against Wegovy injections, which will support subsequent Phase 2 dose-ranging studies.
- Technological Innovation: NPM-139 is a miniature ultra-long-acting semaglutide implant utilizing Vivani's NanoPortal platform technology, designed to offer patients a convenient treatment option that caters to the demand for annual or biannual therapies.
- Market Reaction: In pre-market trading on Nasdaq, Vivani's shares fell 1.54% to $1.32, while Novo Nordisk's shares rose 2.05% to $50.27, reflecting cautious optimism in the market regarding the new partnership.
See More
Vivani Medical Partners with Novo Nordisk to Evaluate NanoPortal Implant for Semaglutide
- Strategic Partnership: Vivani Medical (VANI) has entered into an agreement with Novo Nordisk (NVO) to evaluate its NanoPortal implant NPM-139 for the long-term administration of semaglutide, marketed as Wegovy for weight loss, indicating Novo Nordisk's interest in Vivani's technology.
- Clinical Trial Plans: The NPM-139, based on the NanoPortal platform, is currently undergoing studies for chronic weight management, with a Phase 1 trial expected to begin in mid-2026 to compare the implant against Wegovy injections, aiming to provide patients with a more convenient weight loss treatment option.
- Market Potential: Vivani's implant is anticipated to offer patients a once or twice-yearly treatment option for weight loss therapies, which could revolutionize the existing weight management market by enhancing patient adherence and treatment outcomes.
- Industry Outlook: This collaboration not only showcases Vivani's technological capabilities in the MedTech sector but also opens new avenues for Novo Nordisk's expansion in the weight loss drug market, reflecting a joint effort to address the growing obesity crisis.
See More
Vivani Signs New Agreement with Novo Nordisk for NPM-139 Evaluation
- New Agreement Signed: Vivani Medical has signed an agreement with Novo Nordisk to allow the latter to evaluate NPM-139, a semaglutide drug implant for chronic weight management, indicating Novo Nordisk's interest in Vivani's technology and potentially paving the way for future collaboration.
- Technology Platform Utilization: NPM-139 leverages Vivani's NanoPortal™ platform technology, aiming to provide convenient treatment options for patients who prefer once or twice-yearly treatments, thereby enhancing patient adherence and treatment outcomes.
- Clinical Trial Plans: Vivani expects to initiate a Phase 1 randomized clinical trial for NPM-139 in mid-2026, comparing its safety and tolerability with Wegovy® injections, with successful results supporting a subsequent Phase 2 dose-ranging study.
- Market Potential Outlook: Vivani CEO Adam Mendelsohn stated that this agreement reinforces confidence in the market opportunity for GLP-1 implants, indicating the company's strategic positioning in chronic disease treatment, which may lay the groundwork for future growth.
See More
ClearOne's Strategic Shift and Merger with Cortigent
- Strategic Pivot: ClearOne divested its legacy assets to Biamp in October last year, successfully pivoting into the medical technology sector, with former shareholders retaining approximately 12.7% to 14.4% of the new entity, indicating potential in the new market.
- Reverse Merger Agreement: The announcement of a reverse merger with Cortigent, a unit of Vivani Medical, led to a more than 170% surge in CLRO stock, reflecting strong market recognition and investor optimism regarding the new business model.
- Terms of the Deal: Under the agreement, Vivani will receive 12.5 million shares of ClearOne, gaining control of 59.4% to 67.5% of the combined entity, with Cortigent becoming the surviving entity, marking a new beginning for ClearOne in the medical technology field.
- Funding Plan: ClearOne aims to raise up to $15 million concurrently with the deal's closing, providing a strong foundation for the combined company to advance its product pipeline and further solidify its market position.
See More
Vivani Medical Appoints August Moretti to Board of Directors
- New Board Member: Vivani Medical has appointed August Moretti to its board, whose extensive experience across all phases of company growth will be instrumental in advancing the clinical development of NPM-139 and leveraging NanoPortal™ technology.
- Board Transition: Concurrently, Dr. Dean Baker announced his retirement, concluding a distinguished tenure during which he provided critical guidance for the company's merger, reflecting the company's ongoing adaptability and leadership evolution.
- Technological Development Strategy: Vivani is leveraging its proprietary NanoPortal™ technology to develop ultra-long-acting drug implants aimed at addressing medication adherence issues for chronic disease patients, which is expected to significantly enhance patient treatment experiences.
- Market Potential: The company is developing GLP-1 based implants to tackle metabolic diseases, including obesity and type-2 diabetes, which are anticipated to provide patients with more stable drug delivery, thereby enhancing market competitiveness.
See More
Vivani Receives Approval for SLIM-1 Clinical Trial in Australia
- Clinical Trial Launch: Vivani Medical has received approval from Bellberry in Australia to initiate the SLIM-1 trial for NPM-139, expected to commence in mid-2026, marking a significant advancement in the biopharmaceutical sector and potentially accelerating drug development.
- Trial Design Details: SLIM-1 will evaluate the safety and tolerability of low-dose NPM-139 (semaglutide NanoPortal implant) compared to Wegovy, involving 10 obese or overweight participants over a four-week duration, aimed at providing critical data for future studies.
- Market Demand Expectations: CEO Adam Mendelsohn indicated strong market demand for miniature, reversible GLP-1 implant technology, with Vivani committed to meeting this need and advancing the clinical program for NPM-139 to enhance patient adherence to medication.
- Future Development Plans: While SLIM-1 is underway, Vivani is preparing for SLIM-2, which will focus on dose-ranging efficacy trials pending successful results from SLIM-1, further accelerating the development timeline for NPM-139.
See More
Vivani Medical Partners with Novo Nordisk for Semaglutide Implant Evaluation
- New Agreement: Vivani Medical has entered into a partnership with Novo Nordisk to evaluate its NPM-139 semaglutide implant for chronic weight management, marking a significant collaboration in the biopharmaceutical sector.
- Clinical Trial Plans: Vivani expects to initiate a Phase 1 randomized clinical trial for NPM-139 in mid-2026, comparing its safety and tolerability against Wegovy injections, which will support subsequent Phase 2 dose-ranging studies.
- Technological Innovation: NPM-139 is a miniature ultra-long-acting semaglutide implant utilizing Vivani's NanoPortal platform technology, designed to offer patients a convenient treatment option that caters to the demand for annual or biannual therapies.
- Market Reaction: In pre-market trading on Nasdaq, Vivani's shares fell 1.54% to $1.32, while Novo Nordisk's shares rose 2.05% to $50.27, reflecting cautious optimism in the market regarding the new partnership.
See More
Vivani Medical Partners with Novo Nordisk to Evaluate NanoPortal Implant for Semaglutide
- Strategic Partnership: Vivani Medical (VANI) has entered into an agreement with Novo Nordisk (NVO) to evaluate its NanoPortal implant NPM-139 for the long-term administration of semaglutide, marketed as Wegovy for weight loss, indicating Novo Nordisk's interest in Vivani's technology.
- Clinical Trial Plans: The NPM-139, based on the NanoPortal platform, is currently undergoing studies for chronic weight management, with a Phase 1 trial expected to begin in mid-2026 to compare the implant against Wegovy injections, aiming to provide patients with a more convenient weight loss treatment option.
- Market Potential: Vivani's implant is anticipated to offer patients a once or twice-yearly treatment option for weight loss therapies, which could revolutionize the existing weight management market by enhancing patient adherence and treatment outcomes.
- Industry Outlook: This collaboration not only showcases Vivani's technological capabilities in the MedTech sector but also opens new avenues for Novo Nordisk's expansion in the weight loss drug market, reflecting a joint effort to address the growing obesity crisis.
See More
Vivani Signs New Agreement with Novo Nordisk for NPM-139 Evaluation
- New Agreement Signed: Vivani Medical has signed an agreement with Novo Nordisk to allow the latter to evaluate NPM-139, a semaglutide drug implant for chronic weight management, indicating Novo Nordisk's interest in Vivani's technology and potentially paving the way for future collaboration.
- Technology Platform Utilization: NPM-139 leverages Vivani's NanoPortal™ platform technology, aiming to provide convenient treatment options for patients who prefer once or twice-yearly treatments, thereby enhancing patient adherence and treatment outcomes.
- Clinical Trial Plans: Vivani expects to initiate a Phase 1 randomized clinical trial for NPM-139 in mid-2026, comparing its safety and tolerability with Wegovy® injections, with successful results supporting a subsequent Phase 2 dose-ranging study.
- Market Potential Outlook: Vivani CEO Adam Mendelsohn stated that this agreement reinforces confidence in the market opportunity for GLP-1 implants, indicating the company's strategic positioning in chronic disease treatment, which may lay the groundwork for future growth.
See More
ClearOne's Strategic Shift and Merger with Cortigent
- Strategic Pivot: ClearOne divested its legacy assets to Biamp in October last year, successfully pivoting into the medical technology sector, with former shareholders retaining approximately 12.7% to 14.4% of the new entity, indicating potential in the new market.
- Reverse Merger Agreement: The announcement of a reverse merger with Cortigent, a unit of Vivani Medical, led to a more than 170% surge in CLRO stock, reflecting strong market recognition and investor optimism regarding the new business model.
- Terms of the Deal: Under the agreement, Vivani will receive 12.5 million shares of ClearOne, gaining control of 59.4% to 67.5% of the combined entity, with Cortigent becoming the surviving entity, marking a new beginning for ClearOne in the medical technology field.
- Funding Plan: ClearOne aims to raise up to $15 million concurrently with the deal's closing, providing a strong foundation for the combined company to advance its product pipeline and further solidify its market position.
See More
Vivani Medical Appoints August Moretti to Board of Directors
- New Board Member: Vivani Medical has appointed August Moretti to its board, whose extensive experience across all phases of company growth will be instrumental in advancing the clinical development of NPM-139 and leveraging NanoPortal™ technology.
- Board Transition: Concurrently, Dr. Dean Baker announced his retirement, concluding a distinguished tenure during which he provided critical guidance for the company's merger, reflecting the company's ongoing adaptability and leadership evolution.
- Technological Development Strategy: Vivani is leveraging its proprietary NanoPortal™ technology to develop ultra-long-acting drug implants aimed at addressing medication adherence issues for chronic disease patients, which is expected to significantly enhance patient treatment experiences.
- Market Potential: The company is developing GLP-1 based implants to tackle metabolic diseases, including obesity and type-2 diabetes, which are anticipated to provide patients with more stable drug delivery, thereby enhancing market competitiveness.
See More
Vivani Receives Approval for SLIM-1 Clinical Trial in Australia
- Clinical Trial Launch: Vivani Medical has received approval from Bellberry in Australia to initiate the SLIM-1 trial for NPM-139, expected to commence in mid-2026, marking a significant advancement in the biopharmaceutical sector and potentially accelerating drug development.
- Trial Design Details: SLIM-1 will evaluate the safety and tolerability of low-dose NPM-139 (semaglutide NanoPortal implant) compared to Wegovy, involving 10 obese or overweight participants over a four-week duration, aimed at providing critical data for future studies.
- Market Demand Expectations: CEO Adam Mendelsohn indicated strong market demand for miniature, reversible GLP-1 implant technology, with Vivani committed to meeting this need and advancing the clinical program for NPM-139 to enhance patient adherence to medication.
- Future Development Plans: While SLIM-1 is underway, Vivani is preparing for SLIM-2, which will focus on dose-ranging efficacy trials pending successful results from SLIM-1, further accelerating the development timeline for NPM-139.
See More
